Agilent Technologies, Inc. (NYSE:A) had its price objective boosted by investment analysts at Janney Montgomery Scott from $65.00 to $70.00 in a report released on Wednesday. The firm currently has a “buy” rating on the medical research company’s stock. Janney Montgomery Scott’s price target points to a potential upside of 17.88% from the stock’s previous close.

Several other research analysts have also recently commented on the stock. Bank of America Corporation reaffirmed a “buy” rating on shares of Agilent Technologies in a report on Tuesday. J P Morgan Chase & Co reissued an “overweight” rating and issued a $70.00 price objective on shares of Agilent Technologies in a research note on Wednesday. BidaskClub cut shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Jefferies Group LLC reissued a “buy” rating and issued a $66.00 price objective on shares of Agilent Technologies in a research note on Wednesday, August 9th. Finally, Barclays PLC reissued a “buy” rating and issued a $67.00 price objective on shares of Agilent Technologies in a research note on Wednesday, July 19th. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $61.36.

Agilent Technologies (A) traded up 3.91% during midday trading on Wednesday, hitting $61.70. The stock had a trading volume of 3,134,813 shares. The company has a market cap of $19.83 billion, a price-to-earnings ratio of 34.68 and a beta of 1.30. The company’s 50 day moving average is $60.10 and its 200 day moving average is $55.96. Agilent Technologies has a 1-year low of $42.92 and a 1-year high of $62.42.

Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 13.41% and a return on equity of 16.49%. The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period last year, the firm earned $0.49 earnings per share. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, equities analysts anticipate that Agilent Technologies will post $2.23 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/agilent-technologies-inc-a-pt-raised-to-70-00-at-janney-montgomery-scott/1495268.html.

In other Agilent Technologies news, insider Patrick Kaltenbach sold 5,000 shares of the business’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $61.26, for a total transaction of $306,300.00. Following the sale, the insider now owns 45,138 shares of the company’s stock, valued at $2,765,153.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael R. Mcmullen sold 50,000 shares of the business’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $59.86, for a total transaction of $2,993,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 112,608 shares of company stock worth $6,737,509.

Several institutional investors have recently modified their holdings of the company. Creative Planning raised its position in shares of Agilent Technologies by 6.3% in the first quarter. Creative Planning now owns 11,961 shares of the medical research company’s stock worth $632,000 after buying an additional 710 shares during the period. Capstone Asset Management Co. raised its position in shares of Agilent Technologies by 7.4% in the first quarter. Capstone Asset Management Co. now owns 43,126 shares of the medical research company’s stock worth $2,280,000 after buying an additional 2,990 shares during the period. DnB Asset Management AS raised its position in shares of Agilent Technologies by 14.1% in the first quarter. DnB Asset Management AS now owns 40,449 shares of the medical research company’s stock worth $2,139,000 after buying an additional 5,000 shares during the period. Coastline Trust Co acquired a new position in shares of Agilent Technologies during the first quarter worth approximately $277,000. Finally, Boston Advisors LLC raised its position in shares of Agilent Technologies by 27.7% in the first quarter. Boston Advisors LLC now owns 40,302 shares of the medical research company’s stock worth $2,131,000 after buying an additional 8,730 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.